EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events

Hirotaka Suto

In Vivo · 2025

DOI: 10.21873/invivo.13983 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift In Vivo, 2025. Verfasst von Hirotaka Suto. Beteiligte Einrichtung: Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan hirotaka.suto@hyogo-cc.jp. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions, Neoplasms, Immunotherapy. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-related adverse events (irAEs) are excessive immune responses resembling autoimmune diseases, induced by immune checkpoint inhibitors (ICIs), and can affect organs throughout the body. In contrast to AEs associated with conventional cytotoxic anticancer agents, irAEs may persist or recur after treatment discontinuation. The risk of irAEs recurrence is thought to vary depending on the type and severity of the initial irAE, while the response rate depends on the type and sequence of ICIs re-administered. Therefore, the decision to resume ICI therapy depends on the type and severity of prior irAEs, as well as the anticipated benefits and risks of resumption. This review focuses on the risks and benefits of resuming ICI therapy after each irAE and summarizes the procedure for its resumption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsNeoplasmsImmunotherapyHumansAutoimmune Diseases

Stichwörter der Autor:innen

Immune checkpoint inhibitor rechallengecorticosteroidimmune-related adverse eventimmunomodulatorreview

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan hirotaka.suto@hyogo-cc.jp.

Zitieren

APA

Suto, H. (2025). Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events. In Vivo. https://doi.org/10.21873/invivo.13983

Vancouver

Suto H. Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events. In Vivo. 2025. doi:10.21873/invivo.13983

BibTeX
@article{Suto2025,
  author = {Suto, Hirotaka},
  title = {Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13983}
}
Kostenlos starten →